BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hodgkins KS, Bobrowski AE, Lane JC, Langman CB. Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol 2012;35:394-400. [PMID: 22517061 DOI: 10.1159/000337954] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Java A, Atkinson J, Salmon J. Defective complement inhibitory function predisposes to renal disease. Annu Rev Med 2013;64:307-24. [PMID: 23121180 DOI: 10.1146/annurev-med-072211-110606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
2 Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2019;34:2261-77. [PMID: 30402748 DOI: 10.1007/s00467-018-4091-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
3 Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73:2053-2066. [PMID: 24249647 DOI: 10.1007/s40265-013-0147-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
4 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
5 Garlo K, Dressel D, Savic M, Vella J. Successful eculizumab treatment of recurrent postpartum atypical hemolytic uremic syndrome after kidney transplantation. Clin Nephrol Case Stud 2015;3:8-13. [PMID: 29043127 DOI: 10.5414/CNCS108491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Keating GM. Eculizumab: a guide to its use in atypical haemolytic uraemic syndrome. Drugs Ther Perspect 2014;30:166-72. [DOI: 10.1007/s40267-014-0120-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Kaplan BS, Ruebner RL, Copelovitch L. Eculizumab treatment of atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2012. [DOI: 10.1080/21678707.2013.750579] [Reference Citation Analysis]
8 Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014;12:1440-8. [DOI: 10.1111/jth.12615] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 8.0] [Reference Citation Analysis]
9 Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 2015;30:775-81. [PMID: 25416628 DOI: 10.1007/s00467-014-2990-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
10 Mizuno M, Ito Y, Morgan BP. Exploiting the nephrotoxic effects of venom from the sea anemone, Phyllodiscus semoni, to create a hemolytic uremic syndrome model in the rat. Mar Drugs 2012;10:1582-604. [PMID: 22851928 DOI: 10.3390/md10071582] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
11 Thajudeen B, Sussman A, Bracamonte E. A case of atypical hemolytic uremic syndrome successfully treated with eculizumab. Case Rep Nephrol Urol 2013;3:139-46. [PMID: 24570684 DOI: 10.1159/000357520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
12 Vester U, Mache CJ. Pharmacological treatment of atypical hemolytic-uremic syndrome. Expert Opinion on Orphan Drugs 2014;2:123-35. [DOI: 10.1517/21678707.2014.872029] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Patel P, Balanchivadze N. Hematologic Findings in Pregnancy: A Guide for the Internist. Cureus 2021;13:e15149. [PMID: 34164247 DOI: 10.7759/cureus.15149] [Reference Citation Analysis]
14 Barnett ANR, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N. The use of eculizumab in renal transplantation. Clin Transplant 2013;27:E216-29. [DOI: 10.1111/ctr.12102] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
15 Lopes D, Gomes AM, Cunha C, Pinto CS, Fidalgo T, Fernandes JC. New combined CFH/MCP mutations and a rare clinical course in atypical haemolytic uraemic syndrome. Clin Kidney J 2015;8:695-7. [PMID: 26613026 DOI: 10.1093/ckj/sfv102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]